104706-47-0 Usage
Description
(R)-(-)-3-Pyrrolidinol hydrochloride, also known as (R)-3-Hydroxypyrrolidine hydrochloride, is a chiral hydroxy derivative of pyrrolidine. It is a light brown crystalline compound with unique chemical properties that make it valuable in various applications across different industries.
Uses
Used in Pharmaceutical Industry:
(R)-(-)-3-Pyrrolidinol hydrochloride is used as a key intermediate in the synthesis of chiral neurologically active compounds. It plays a crucial role in the preparation of muscarinic receptor antagonists, which are essential in the treatment of various conditions such as overactive bladder and chronic obstructive pulmonary disease (COPD). Additionally, it is utilized in the development of antimicrobial agents, contributing to the fight against bacterial infections.
Used as a Darifenacin Intermediate:
In the pharmaceutical industry, (R)-3-Hydroxypyrrolidine hydrochloride is specifically used as an intermediate for the synthesis of darifenacin, a muscarinic receptor antagonist used to treat overactive bladder.
Used in the Synthesis of Biaryl Carboxamide Functional Groups:
(R)-(-)-3-Pyrrolidinol hydrochloride serves as a building block for the synthesis of biaryl carboxamide functional groups containing bis-aminopyrrolidine ureas. These compounds have potential as antagonists of the melanin-concentrating hormone receptor-1, which can be targeted for the treatment of various conditions, including obesity and anxiety.
Used in the Development of Pyrrolidinol-based Ionic Liquids:
(R)-(-)-3-Pyrrolidinol hydrochloride is also used in the creation of pyrrolidinol-based ionic liquids, which have potential applications in various fields, such as green chemistry, electrochemistry, and materials science.
Used in the Synthesis of Optically Active Organocatalysts:
(R)-3-Pyrrolidinol hydrochloride is employed in the synthesis of optically active 2-tritylpyrrolidine-based organocatalysts. These catalysts are essential in asymmetric catalysis, a field that focuses on the selective synthesis of chiral molecules, which are crucial in the pharmaceutical industry for the development of drugs with specific biological activities.
Purification Methods
The (±)-isomer is purified by repeated distillation ( b 102-104o/12mm, 108-110o/18mm), and the (±)-picrate crystallises from EtOH with m 140-141o. The R(+)-enantiomer has b 70o/0.6mm and [] D +5.6o (c 3.63, MeOH). Its hydrochloride has a negative rotation and its dimethiodide has m 230o and [] 24 -8.02o. [Suyama & Kanno Yakugaku Zasshi (J Pharm Soc Japan) 85 531 1965, Uno et al. J Heterocycl Chem 24 1025 1987, Flanagan & Joullie Heterocycles 26 2247 1987, Beilstein 21 III/IV 44.]
Check Digit Verification of cas no
The CAS Registry Mumber 104706-47-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,7,0 and 6 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 104706-47:
(8*1)+(7*0)+(6*4)+(5*7)+(4*0)+(3*6)+(2*4)+(1*7)=100
100 % 10 = 0
So 104706-47-0 is a valid CAS Registry Number.
InChI:InChI=1/C4H9NO.ClH/c5-4-1-2-6-3-4;/h4H,1-3,5H2;1H/t4-;/m1./s1
104706-47-0Relevant articles and documents
COMPOUNDS
-
Page/Page column 117, (2017/02/09)
Disclosed are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis(ALS).
DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF
-
Page/Page column 55, (2012/09/11)
The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
PREPARATION OF DARIFENACIN AND ITS SALTS
-
Page/Page column 15; 32-33, (2008/12/08)
Provided are various processes and compounds related to darifenacin and/or its salts. For example, there is provided a process for preparing a free base of darifenacin: Formula, or the salt thereof, the process including reacting 3-(S)-(cyanodiphenylmethyl)-1-[2-(2,3-dihydrobenzofuran-5-yl) ethyl] pyrrolidine of the Formula (IV), or a salt thereof: Formula (IV) with a base effective to convert the nitrile group of the compound of the Formula (IV) to the amide group of the darifenacin in an organic solvent, the reaction being carried out in the organic solvent, with a proviso that the solvent is not 2-methyl-butan-2-ol, and with further proviso that the reaction produces less than about 0.5 % of the compound of the Formula (Ic): Formula (Ic) in the reaction mass, as measured by HPLC. Various embodiments and variants are provided.